ARVNHealthcare · BiotechnologyThe 16 Wall Street analysts covering Arvinas, Inc. hold a median 12-month price target of $13 — +44.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Arvinas, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (93): The business earns solid, repeatable profits on what it owns.
Accruals (32): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ARVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +44.9% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Citigroup | Maintains | Buy | $24 → $21 |
| 10 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $19 → $14 |
| 5 Aug 2026 | Wedbush | Maintains | Neutral | $11 → $12 |
| 5 Aug 2026 | Wells Fargo | Downgrade | Equal-Weight | $15 → $11 |
| 4 Aug 2026 | BTIG | Reiterates | Buy | $18 |
| 3 June 2026 | Stephens & Co. | Reiterates | Overweight | $18 |
| 3 June 2026 | Stephens & Co. | Reiterates | Overweight | — |
| 13 May 2026 | Barclays | Maintains | Overweight | — |
| 13 May 2026 | BTIG | Maintains | Buy | — |
| 4 May 2026 | Citigroup | Maintains | Buy | — |
| 19 Mar 2026 | BTIG | Maintains | Buy | — |
| 19 Mar 2026 | Citigroup | Maintains | Buy | — |
| 5 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 25 Feb 2026 | Piper Sandler | Reiterates | Overweight | — |
| 25 Feb 2026 | Wedbush | Maintains | Neutral | — |
| 6 Jan 2026 | Citigroup | Upgrade | Buy | — |
| 17 Dec 2025 | Barclays | Maintains | Overweight | — |
| 10 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 6 Nov 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARVN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 24% of US stocks
Cheaper than 56% of US stocks
Cheaper than 72% of US stocks
Cheaper than 73% of US stocks
Higher than 99% of US stocks
Higher than 97% of US stocks
Higher than 99% of US stocks
Higher than 55% of US stocks
Higher than 46% of US stocks
Higher than 39% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Arvinas, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Arvinas (ARVN) was upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. The upgrade could influence the stock's performance in the near term.
Why it matters — ARVN watchers would care because the upgrade signals improved expectations for the company's earnings outlook as assessed by Zacks.
Seeking Alpha published a transcript of Arvinas, Inc.'s Q2 2026 earnings call. The transcript covers the company's second-quarter 2026 results discussion.
Why it matters — A transcript of Arvinas's Q2 2026 earnings call gives ARVN watchers direct access to management's commentary on the quarter's results.
In its Q2 2026 earnings call, Arvinas said it is concentrating resources on its early-stage oncology and neurology pipeline after strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals.
Why it matters — Arvinas watchers would care because the FDA approval of VEPPANU and the Rigel out-licensing deal, along with the announced shift in resource focus, mark a significant strategic milestone for the company.
Arvinas reported Q2 earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share in the same quarter a year ago.
Why it matters — ARVN watchers would note that the company's quarterly earnings came in well above analyst expectations and turned sharply higher versus the year-ago period.
Arvinas reported second quarter 2026 financial results, noting the first regulatory approval of a PROTAC drug (VEPPANU) and its out-licensing to Rigel Pharmaceuticals. The company also expects to share clinical data from three Phase 1 programs over the next 12 months and presented preclinical data for its HPK1 degrader program.
Why it matters — The first-ever regulatory approval of a PROTAC drug marks a key milestone for Arvinas' platform technology, and upcoming clinical readouts for ARV-393, ARV-102, and ARV-027 will be closely watched by investors.
The 16 Wall Street analysts covering Arvinas, Inc. have a median 12-month price target of $13, with estimates ranging from $6 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Arvinas, Inc., 7 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Arvinas, Inc. 84 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Arvinas, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +44.9% from the last close, and Ticker Nerd's factor model ranks Arvinas, Inc. 84 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Arvinas, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $21 over the next 12 months.
Arvinas, Inc. returned +26.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Arvinas Inc. is a clinical-stage biotechnology company focused on discovering, developing, and advancing proteolysis targeting chimeras (PROTAC) targeted protein degraders.
The most recent item we track (Zacks Investment Research, 6 Aug 2026): "Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know". Arvinas (ARVN) was upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. The upgrade could influence the stock's performance in the near term.
Arvinas Inc. is a clinical-stage biotechnology company focused on discovering, developing, and advancing proteolysis targeting chimeras (PROTAC) targeted protein degraders. These innovative therapies harness the body's natural protein disposal system to selectively degrade and remove disease-causing proteins, enabling treatment of previously undruggable targets in oncology and neurodegenerative disorders. Its pipeline features investigational candidates such as vepdegestrant for ESR1-mutated, ER-positive/HER2-negative advanced breast cancer; bavdegalutamide (ARV-110) and ARV-766 for metastatic castration-resistant prostate cancer targeting the androgen receptor; ARV-471 for metastatic ER-positive/HER2-negative breast cancer; ARV-102 for Parkinson's disease; and ARV-806 for KRAS G12D-mutated cancers including pancreatic, colorectal, and lung types. Arvinas Inc. generates revenue through strategic partnerships, licensing agreements, and clinical milestones, positioning it as a leader in targeted protein degradation within the biotechnology sector. Founded in 2013 and headquartered in New Haven, Connecticut, the company advances multiple programs through clinical trials and regulatory submissions.
CEO Dr. Randy Teel Ph.D. · 246 employees · United States · https://www.arvinas.com